Search Our Scientific Publications & Authors

Int Urol Nephrol 2022 May 27. Epub 2022 May 27.

Assuta Medical Center, POB 229, 9093500, Bet Horon, Israel.

Purpose: Transcutaneous posterior tibial nerve stimulation (TPTNS) for the treatment of overactive bladder syndrome (OAB), with or without urge urinary incontinence (UUI) using electrodes imbedded in the fabric of a conventional sock and an attachable battery-operated stimulation device (ZIDA-Exodus Innovations, Sufa, Israel), was compared for effectiveness and safety to a sham procedure in a prospective, blinded, randomized, controlled trial.

Methods: Forty patients with diagnosed with OAB were recruited from a single site. There were two groups: a treatment group (21 patients, mean age 64), which used an active ZIDA activation device (ZIDA) and a sham control group (SCG, 19 patients, mean age 72) randomized in a 1:1 ratio. Read More

Can Urol Assoc J 2022 May 20. Epub 2022 May 20.

Division of Urology, CHU de Québec - Université Laval Research Center, Quebec, QC, Canada.

Introduction: In 2017, propiverine was approved in Canada for overactive bladder (OAB) in adults and children. There is, however, scarce data on its efficacy and tolerability in the pediatric population. Our primary objective was to assess the efficacy and tolerability of propiverine as a treatment for pediatric OAB. Read More

J Health Econ Outcomes Res 2018 9;5(2):194-205. Epub 2018 Jan 9.

Medical and Regulatory Affairs Department, Laboratorios Gebro Pharma S.A., Barcelona , Spain.

This study evaluated the clinical outcomes and economic results of transdermal oxybutynin compared to fesoterodine, tolterodine, solifenacin, oxybutynin, trospium chloride, and mirabegron for overactive bladder syndrome in Spain. A Markov model was built with monthly cycles for a 5-year time frame. The model reflected clinical events, discontinuation, dose scaling and change in treatment according to actual clinical practice. Read More

Int J Pharm 2022 May 23:121849. Epub 2022 May 23.

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.

Discontinued treatment and non-adherence are oftentimes weaknesses of common first-line drug therapy against bladder conditions due to their negative side-effects. To overcome these limitations and increase patients' quality of life, intravesical therapies are continuously being explored. 3D-printing offers the possibility of freely tailoring drug delivery systems to manufacture indwelling devices that may administer drugs locally over an extended time and avoiding frequently repeated administrations while minimizing systemic side-effects. Read More

Int J Gynaecol Obstet 2022 May 26. Epub 2022 May 26.

ASST Santi Paolo e Carlo, Ospedale San Paolo, Milano, Italy.

Objective: The coexisting overactive-underactive bladder (COUB) syndrome could be related to the increased urethral resistance caused by severe pelvic organ prolapse (POP). We aimed to evaluate the clinical and urodynamic findings of patients with COUB and/or detrusor overactivity-underactivity (DOU) in a cohort of patients scheduled for POP surgery and the possible risk factors of COUB after surgery.

Methods: This retrospective study analyzed all patients who underwent POP repair between 2008 and 2013, excluding women with history of previous pelvic floor surgery. Read More